Administration safety

how to take retatrutide

Published May 2, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

Retatrutide has been studied as a once-weekly subcutaneous injection, but that does not create public-use instructions.

Direct answer

In Lilly clinical studies, retatrutide is taken as a once-weekly subcutaneous injection. Outside a Lilly clinical trial, it is not approved or publicly available, so this page does not provide personal administration instructions.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quote10-fold dosing errors

Lambson et al., JAPhA 2023 compounded semaglutide administration-error case series

This case series supports warnings about vials, syringe units, and self-measured injectable dosing errors.

Short source quotepreparation errors

McCall et al., Expert Opinion on Drug Safety 2026 compounded GLP-1 pharmacovigilance study

This pharmacovigilance study is relevant to compounded GLP-1 safety signals and product-quality concerns.

Short source quotecontamination or concentration

Watson et al., Journal of Medical Toxicology 2021 systematic review of compounding errors

This systematic review supports broader warnings about compounding errors, contamination, and concentration risk.

What to know before acting on this search

Clinical-trial administration happens under a study protocol with screening, monitoring, and adverse-event reporting.
A product claiming to be retatrutide online is not the same thing as a regulated, approved medicine.
If you are looking for treatment, ask a licensed clinician about approved GLP-1 or GIP/GLP-1 options instead.

Safety and compliance notes

Self-administering an unapproved injectable can introduce dose, sterility, storage, and counterfeit risks.
FDA warns against products sold falsely for research purposes or not for human consumption when marketed to consumers.
Do not translate clinical trial descriptions into a home-use protocol.

Safer next step

Start with approval status and clinical-trial availability before considering any treatment discussion.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.